Persistent Asset Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Persistent Asset Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,001	Closed	-$181K	–	865
2026 Q1	$181K	Buy	+9,001	New	+$145K	0.07%	204
2025 Q2	–	Sell	-34,098	Closed	-$393K	–	212
2025 Q1	$393K	Sell	34,098 -7,854	-19%	-$80.2K	0.33%	69
2024 Q4	$374K	Buy	+41,952	New	+$434K	0.31%	72

Other funds holding KALV

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Persistent Asset Partners's KALV Position: Q2 2026 in Review

Persistent Asset Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 9,001 shares — an estimated $181K sold.

Persistent Asset Partners first reported a position in KALV in Q4 2024 and held it in 3 quarters. The position peaked at $393K in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Persistent Asset Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Persistent Asset Partners sold 9,001 KalVista Pharmaceuticals shares in Q2 2026, an estimated $181K.
Persistent Asset Partners first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 3 quarters.
Persistent Asset Partners's KalVista Pharmaceuticals position peaked at $393K in Q1 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.